A Grounded Theory of Sport Injury-Related Growth

Although previous research has shown that experiencing an injury can act as a catalyst for self-development, research that has examined the concept of sport injury-related growth (SIRG) remains largely descriptive. This study aimed to address this by developing a substantive theory to explain the processes through which injured athletes experienced SIRG. Using Strauss and Corbin’s (1998) variant of grounded theory, 37 injured athletes competing in a range of sports and competitive levels participated in qualitative interviews. Interviews (N=70) and data analysis were conducted over a period of 24 months. Transcripts were analyzed using open, axial, and selective coding. Quality criteria used were fit, relevance, workability, and modifiability. The grounded theory produced (i.e., Theory of Sport Injury-Related Growth) suggests a number of internal (i.e., personality, coping styles, knowledge and prior experience, and perceived social support) and external factors (i.e., cultural scripts, physical resources, time, and received social support) enable injured athletes to transform their injury into an opportunity for growth and development. The mechanisms through which this occurs are meta-cognitions, positive reappraisal, positive emotions, and facilitative responses. This theory offers a number of exciting avenues for future research, and provides medical personnel and practicing sport psychologists with a detailed explanation of how sport injury can lead to growth experiences

Sport Psychology Consultants’ Perspectives on Facilitating Sport Injury-Related Growth

Despite recent conceptual, methodological, and theoretical advancements on sport injury-related 26 growth (SIRG), there is no research on sport psychology consultants’ (SPCs) experiential 27 knowledge of working with injured athletes to promote SIRG. Toward this end, this study examined 28 SPCs’ perspectives on facilitating SIRG to provide an evidence-base for professional practice. 29 Participants were purposefully sampled (4 females, 6 males; Mean of 19 years’ applied experience) 30 and interviewed. Transcripts were thematically analyzed. Methodological rigor and generalizability 31 were maximized through self-reflexivity and eliciting external reflections. Five themes were 32 identified: Hear the Story, Contextualize the Story, Reconstruct the Story, Live the Story, and Share 33 the Story. Findings offer practitioners a novel approach to working with injured athletes. Rather than 34 focusing on returning to preinjury level of functioning, the findings illustrate how SPCs can work 35 with injured athletes to help transform injury into an opportunity to bring about positive change

A Systematic Review of Interventions to Promote Growth Following Adversity

Background: Athletes experience adversity across many aspects of their lives. Challenging the dominant idea that adversity is just a negative experience, a significant body of research in sport has demonstrated that these adverse events can also act as catalysts for positive change (Howells, Fletcher, & Sarkar, 2017). Yet, a limited number of researchers have focused on how to promote growth following adversity in sport. To support this line of inquiry our aim in this study was to facilitate knowledge transfer from other psychology disciplines by systematically reviewing intervention studies that aim to foster growth following adversity. Methods: We conducted the systematic review using PRISMA guidelines. Following inclusion and exclusion criteria, we appraised the studies using the Mixed Methods Appraisal Tool (Pluye & Hong, 2014). Results: Thirty-six studies were included in the review. We synthesized the studies in relation to participant characteristics (i.e., sample size, age, gender, ethnicity, adversity), study characteristics (i.e., design, content, duration, delivery, outcome measures), intervention outcomes (i.e., statistical significance, effect size, qualitative indicators of growth), antecedents (viz. mediators, moderators), and quality appraisal. Conclusion: In the discussion we critically consider the lessons sport and exercise psychology researchers can learn from published intervention studies from other fields of research (e.g., the use of meaningful metrics, that there are different trajectories of growth, growth is a multidimensional phenomenon). Future researchers should seek to build on findings to advance knowledge and understanding in the most significant and meaningful ways

Exponential growth, high prevalence of SARS-CoV-2, and vaccine effectiveness associated with the Delta variant

SARS-CoV-2 infections were rising during early summer 2021 in many countries associated with the Delta variant. We assessed RT-PCR swab-positivity in the REal-time Assessment of Community Transmission-1 (REACT-1) study in England. We observed sustained exponential growth with average doubling time (June-July 2021) of 25 days driven by complete replacement of Alpha variant by Delta, and by high prevalence at younger less-vaccinated ages. Unvaccinated people were three times more likely than double-vaccinated people to test positive. However, after adjusting for age and other variables, vaccine effectiveness for double-vaccinated people was estimated at between ~50% and ~60% during this period in England. Increased social mixing in the presence of Delta had the potential to generate sustained growth in infections, even at high levels of vaccination

Genomic investigations of unexplained acute hepatitis in children

Since its first identification in Scotland, over 1,000 cases of unexplained paediatric hepatitis in children have been reported worldwide, including 278 cases in the UK1. Here we report an investigation of 38 cases, 66 age-matched immunocompetent controls and 21 immunocompromised comparator participants, using a combination of genomic, transcriptomic, proteomic and immunohistochemical methods. We detected high levels of adeno-associated virus 2 (AAV2) DNA in the liver, blood, plasma or stool from 27 of 28 cases. We found low levels of adenovirus (HAdV) and human herpesvirus 6B (HHV-6B) in 23 of 31 and 16 of 23, respectively, of the cases tested. By contrast, AAV2 was infrequently detected and at low titre in the blood or the liver from control children with HAdV, even when profoundly immunosuppressed. AAV2, HAdV and HHV-6 phylogeny excluded the emergence of novel strains in cases. Histological analyses of explanted livers showed enrichment for T cells and B lineage cells. Proteomic comparison of liver tissue from cases and healthy controls identified increased expression of HLA class 2, immunoglobulin variable regions and complement proteins. HAdV and AAV2 proteins were not detected in the livers. Instead, we identified AAV2 DNA complexes reflecting both HAdV-mediated and HHV-6B-mediated replication. We hypothesize that high levels of abnormal AAV2 replication products aided by HAdV and, in severe cases, HHV-6B may have triggered immune-mediated hepatic disease in genetically and immunologically predisposed children

Symptomology following mRNA vaccination against SARS-CoV-2

Despite demonstrated efficacy of vaccines against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the causative agent of coronavirus disease-2019 (COVID-19), widespread hesitancy to vaccination persists. Improved knowledge regarding frequency, severity, and duration of vaccine-associated symptoms may help reduce hesitancy. In this prospective observational study, we studied 1032 healthcare workers who received both doses of the Pfizer-BioNTech SARS-CoV-2 mRNA vaccine and completed post-vaccine symptom surveys both after dose 1 and after dose 2. We defined appreciable post-vaccine symptoms as those of at least moderate severity and lasting at least 2 days. We found that symptoms were more frequent following the second vaccine dose than the first (74% vs. 60%, P < 0.001), with >80% of all symptoms resolving within 2 days. The most common symptom was injection site pain, followed by fatigue and malaise. Overall, 20% of participants experienced appreciable symptoms after dose 1 and 30% after dose 2. In multivariable analyses, female sex was associated with greater odds of appreciable symptoms after both dose 1 (OR, 95% CI 1.73, 1.19-2.51) and dose 2 (1.76, 1.28-2.42). Prior COVID-19 was also associated with appreciable symptoms following dose 1, while younger age and history of hypertension were associated with appreciable symptoms after dose 2. We conclude that most post-vaccine symptoms are reportedly mild and last <2 days. Appreciable post-vaccine symptoms are associated with female sex, prior COVID-19, younger age, and hypertension. This information can aid clinicians in advising patients on the safety and expected symptomatology associated with vaccination